Phase Ib of Cyclophosphamide, Pomalidomide, Dexamethasone and Daratumumab (CPD-DARA) in Patients With Relapsed/Refractory Multiple Myeloma. (The CPD-DARA Study)
Latest Information Update: 19 Sep 2024
At a glance
- Drugs Cyclophosphamide (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Acronyms CPD-DARA
- 23 Oct 2023 Status changed from recruiting to active, no longer recruiting.
- 01 Oct 2023 According to Janssen Pharmaceuticals media release, Janssen Pharmaceuticals has changed its name to Johnson & Johnson Innovative Medicine
- 23 Jan 2023 Planned End Date changed from 1 Mar 2025 to 30 Apr 2026.